Finland· FI-REL-REL53692

Recarbrio

A imipenem, cilastatin and relebactam product containing imipenem monohydrate + cilastatin sodium + relebactam monohydrate, registered in Finland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC J01DH56

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedRecarbrioATCJ01DH56REGISTER NO.FI-REL-REL53692PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Imipenem, cilastatin and relebactam is registered in 11 of 19 countries.

Countries holding a registration under ATC J01DH56 (imipenem, cilastatin and relebactam), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 7 of them publish a price we can compare per daily dose

Imipenem, cilastatin and relebactam · ATC J01DH56

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Imipenem monohydrate + Cilastatin sodium + Relebactam monohydrate
Manufacturer
Merck Sharp & Dohme B.V.
Country
Finland (FI)
ATC code
J01DH56
ATC class
Imipenem, cilastatin and relebactam
Defined daily dose
2 g, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/af26be5a-af4c-4387-9499-c27e92d9269b
GET /v1/drugs/af26be5a-af4c-4387-9499-c27e92d9269b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "2",
  "form": "infuusiokuiva-aine, liuosta varten",
  "route": "Laskimoon",
  "ddd_unit": "g",
  "strength": "500 mg / 500 mg / 250 mg",
  "atc_label": "imipeneemi,silastatiini ja relebaktaami",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/19/1420/001",
  "fimea_rel_id": "REL53692",
  "authorised_at": "2020-02-13"
}

See everything about imipenem, cilastatin and relebactam.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.